Cisapride Capsules

Gastrointestinal motility effects: Esophagus: This product can enhance esophageal motility and lower esophageal sphincter tension; This product can prevent gastric contents from reflux into the esophagus and improve esophageal clearance; Stomach: This product can increase gastric and duodenal contractility and coordination between the antrum and duodenum; This product can reduce duodenal-gastric reflux; This product can improve gastric and duodenal emptying; Intestine: This product can enhance intestinal motility and promote small and large intestine transit. Other effects: Since this product lacks cholinergic effects, it does not increase basal and pentagastrin-induced gastric acid secretion; Since this product relatively lacks dopamine antagonist properties, it has almost no effect on plasma prolactin levels; <br

The main ingredient of this product is cisapride

This product is a capsule, the contents are white or off-white powder, odorless.

A whole-gastrointestinal prokinetic drug. It is mainly used for functional dyspepsia, upper gastrointestinal discomfort with negative X-ray and endoscopy examinations, with symptoms such as early satiety, fullness after meals, decreased appetite, bloating, excessive belching, lack of appetite, nausea, vomiting or ulcer-like complaints (burning pain in the upper abdomen). It can also be used to treat mild reflux esophagitis.

Oral treatment: Dosage: The maximum daily dose is 30 mg. Adults: Depending on the severity of the disease, the total daily dose is 15-30 mg, divided into 2-3 doses, 5 mg each time (the dose can be doubled). Children weighing 25-50 kg: The maximum dose is 5 mg each time, four times a day. Or as directed by a doctor. Children weighing less than 25 kg: 0.2 mg/kg body weight each time, three to four times a day. Or as directed by a doctor. It is recommended to avoid taking it with grapefruit juice as much as possible. In case of renal insufficiency, it is recommended to reduce the daily dose by half.

Due to the pharmacological activity of this product, transient abdominal cramping, borborygmus, and diarrhea may occur. If abdominal cramping occurs, the dose may be halved. Occasionally, allergic reactions including rash, itching, urticaria, bronchospasm, mild transient headache or dizziness, and dose-related urinary frequency have been reported. Very rare reports of arrhythmias, including ventricular tachycardia, ventricular fibrillation, torsade de pointes, and QT prolongation. Most of these patients often take several other drugs at the same time - including drugs that inhibit the CYP3A4 enzyme, or have heart disease and risk factors for arrhythmias. Rare reports of reversible liver function abnormalities, with or without cholestasis. Although there have been case reports of gynecomastia and galactorrhea in men, the incidence (<

Patients with known allergies to this product are contraindicated. Concomitant oral or parenteral use of drugs that strongly inhibit CYP3A4 enzymes is prohibited, including: triazole antifungal drugs; macrolide antibiotics; HIV protease inhibitors; nefazodone; (see Drug Interactions). Patients with heart disease, arrhythmia, QT interval prolongation are contraindicated, and it is prohibited to use it with drugs that cause QT interval prolongation; patients with water and electrolyte disorders, especially those with hypokalemia or hypomagnesemia, are contraindicated; patients with bradycardia are contraindicated; patients with congenital QT interval prolongation or a family history of congenital QT interval prolongation syndrome are contraindicated; patients with pulmonary, liver, and kidney dysfunction are contraindicated; infants and young children are contraindicated.

Precautions for children: Use with caution in children. Precautions for pregnancy and lactation: Animal reproductive toxicity and teratogenicity studies have shown that this product does not affect embryo formation, has no original embryotoxicity, and has no teratogenic effect. In a large number of population studies, cisapride does not increase fetal malformations. However, pregnant women, especially those in the first three months of pregnancy, should weigh the pros and cons. Although the amount excreted through breast milk is very small, it is still recommended that breastfeeding mothers do not use it. Precautions for the elderly: In elderly patients, due to the moderate delay in the elimination half-life of this product, the steady-state plasma concentration will generally increase, so the therapeutic dose should be reduced and used with caution.

The main metabolic pathway of this product is through CYP3A4 enzyme metabolism. If the drug that can inhibit this enzyme is taken orally or parenterally at the same time, it may lead to an increase in plasma cisapride concentration, thereby increasing the QT interval and the risk of arrhythmia, including ventricular tachycardia, ventricular fibrillation and torsade de pointes. Therefore, it is forbidden to take it at the same time with these drugs.

Store in a dry place at 15-30℃, out of reach of children.

5mg

24 months

Jinzhou Jiutai Pharmaceutical Co., Ltd.

• Founded in:

  1998-09-02

• Address:

  No. 41, Tai'anli, Taihe District, Jinzhou City, Liaoning Province

• Tax NO.:

  91210700242034190P

• Registered Funds:

  40.986462 million yuan

• Website:

  Log in to view

• Email:

  Log in to view